Want to see TSE:PHRM full AI Analyst Report?
PHRM Stock Chart & Stats
C$0.06
<C$0.01(9.09%)
At close: 4:00 PM EDT
C$0.06
<C$0.01(9.09%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.16
Previous CloseN/A
Volume32.78K
Average Volume (3M)46.03K
Market Cap
C$5.46M
Enterprise ValueC$9.70M
Total Cash (Recent Filing)C$921.54K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
Oct 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding91,019,066
10 Day Avg. Volume81,992
30 Day Avg. Volume46,027
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)8.91
Price to Sales (P/S)0.00
P/FCF Ratio-11.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)C$83.60M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no total debt reduces refinancing pressure and interest obligations, giving PharmaTher greater financial flexibility than a similarly early-stage biotech with leverage. This structure can help preserve resources for development activities and reduce balance-sheet risk while the company remains pre-revenue.
Narrowing Net LossesThe substantial reduction in annual net losses indicates improving cost control and a more efficient operating profile. Although profitability remains negative, continued progress could extend the company’s financial runway and reduce the amount of capital required to support its development programs over the next several quarters.
Reduced Operating Cash BurnLower operating cash burn is a constructive trend because it suggests the business is consuming less cash to fund ongoing operations. If maintained, this improvement could slow the need for external financing and provide greater flexibility to advance ketamine-based development programs despite the absence of revenue.
Bears Say
Pre-revenue Business ModelThe absence of reported revenue means PharmaTher has not yet demonstrated commercial demand or a recurring source of operating income. This leaves future progress dependent on development execution and eventual commercialization, while current activities continue without revenue support from an established product base.
Persistent Negative Cash FlowPersistent negative operating and free cash flow shows that the company continues to consume cash rather than generate funding internally. Even with improved burn in 2026, ongoing cash deficits may require external funding and could constrain the pace of development or other strategic investments.
Shrinking Equity BaseThe steep decline in stockholders’ equity indicates that cumulative losses or capital outflows have materially reduced the company’s capital base. This weakens financial flexibility and leaves less balance-sheet capacity to absorb continued losses or fund development before commercial revenue is established.
PharmaTher Holdings Ltd News
PHRM FAQ
What was PharmaTher Holdings Ltd’s price range in the past 12 months?
PharmaTher Holdings Ltd lowest stock price was C$0.04 and its highest was C$0.16 in the past 12 months.
What is PharmaTher Holdings Ltd’s market cap?
PharmaTher Holdings Ltd’s market cap is C$5.46M.
When is PharmaTher Holdings Ltd’s upcoming earnings report date?
PharmaTher Holdings Ltd’s upcoming earnings report date is Oct 28, 2026 which is in 14 days.
How were PharmaTher Holdings Ltd’s earnings last quarter?
PharmaTher Holdings Ltd released its earnings results on Jan 30, 2026. The company reported -C$0.003 earnings per share for the quarter.
Is PharmaTher Holdings Ltd overvalued?
According to Wall Street analysts PharmaTher Holdings Ltd’s price is currently Overvalued.
Does PharmaTher Holdings Ltd pay dividends?
PharmaTher Holdings Ltd does not currently pay dividends.
What is PharmaTher Holdings Ltd’s EPS estimate?
PharmaTher Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaTher Holdings Ltd have?
PharmaTher Holdings Ltd has 91,019,066 shares outstanding.
What happened to PharmaTher Holdings Ltd’s price movement after its last earnings report?
PharmaTher Holdings Ltd reported an EPS of -C$0.003 in its last earnings report. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of PharmaTher Holdings Ltd?
Currently, no hedge funds are holding shares in TSE:PHRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. operates as a clinical-stage biotechnology firm, primarily focused on psychedelic compounds. It is dedicated to investigating, advancing, and bringing to market innovative applications, formulations, and administration techniques for psychedelics to treat a range of conditions including mental health disorders, neurological ailments, and chronic pain. A key asset in its development portfolio is an intravenous ketamine injection, currently undergoing Phase II and III clinical evaluations targeting indications such as Parkinson's disease, anesthesia/sedation, and amyotrophic lateral sclerosis (ALS). The company's pipeline further features a Ketamine Patch, which is progressing through Phase I and II clinical trials for the treatment of depression, various mental health conditions, complex regional pain syndrome (CRPS), and other pain-related disorders. Additionally, a Ketamine Pump is undergoing Phase II clinical assessment for use in mental health, pain management, and surgical/procedural settings. Beyond these, PharmaTher is actively developing PHARMAPATCH, an innovative microneedle patch designed for psychedelic drug delivery. The company has established strategic collaboration agreements with several partners, including LTS Lohmann Therapie-Systeme AG for developing a ketamine microneedle patch; Alcami Corporation for the advancement of ketamine injectables and infusions; BioRAE, Inc. for the development of ketamine pump technology; Revive Therapeutics Ltd. to develop a psilocybin microneedle patch; and Gesval S.A. for the development of patented continuous-flow process technology for synthesizing ketamine and its analogs. PharmaTher is also internally dedicated to creating its own proprietary wearable ketamine delivery system, intended for addressing mental health, neurological, and pain conditions. Established in 2019, the company maintains its headquarters in Toronto, Canada.
Technical Analysis
COSCIENS Biopharma
―
Kane Biotech
―
BetterLife Pharma
―
BioVaxys Technology
―
Marvel Biosciences Corp
―